February 2008
Volume 18, Issue 2


CDC Survey Shows Less Effective Flu Medications Still Used


A recent survey conducted by the Centers for Disease Control and Prevention (CDC) suggests that many primary care physicians (PCPs) prescribed amantadine and rimantadine last influenza season despite a warning about viral resistance. PCPs are also using the rapid antigen test more than any other influenza testing method, which CDC cautioned has low sensitivity.

The survey was sent out to several academic institutions and state health departments in CDC’s Emerging Infections Program. The PCPs were asked which influenza medications they prescribed and which test they used, if any, when evaluating patients with influenza-like illness.

According to CDC, about 25 percent of the PCPs surveyed still prescribed the influenza medicines amantadine and rimantadine. CDC warned in January 2006 that widespread resistance to these drugs had emerged among influenza A strains.

Oseltamivir (Tamiflu) was the most prescribed medication for influenza (87 percent). Zanamivir (Relenza) was the least prescribed medication (5.3 percent).

When the PCPs saw the need for an influenza test, the most frequently used method was the rapid antigen test., The second-most common method was viral culture, followed by a serologic test. Due to low sensitivity of the rapid antigen test, which can miss up to 30 percent of cases, CDC urges physicians to use clinical judgment when testing for influenza.

The survey was published in the January 25, 2008 Morbidity and Mortality Weekly Report (57(03);61-65).



< Previous Article | Next Article >

In the IDSA Journals
Europe Reports High Percentage of Oseltamivir-resistant Influenza Virus
EIN: Decolonize MRSA Patients or Not?
Multidrug-resistant Staph Reported among MSM
Health Alerts, Drug Approvals, Recalls, Adverse Events
IDSA Policy & Advocacy Update: IDSA Opposes Anti-Thimerosal Legislation
CDC Survey Shows Less Effective Flu Medications Still Used
Third Seasonal and Pandemic Influenza Meeting: May 18-20
Meeting on Key Issues in TB Drug Development
Welcome, New IDSA Members!
Calendar of Future Meetings and Events
CMS Requires NPI on Claims Starting March 1

Dates to Remember

Oct. 25-29, 2008
IDSA/ICAAC Joint Meeting
Washington, DC
Abstract submission deadline: May 19, 2008

June 3-4, 2008
Fellows' In-Training Exam

Oct. 29-Nov. 1, 2009
47th Annual Meeting of IDSA
Philadelphia, PA

 



Search Back Issues
Forward this Issue
Print-Friendly Version

Copyright IDSA 2008 Infectious Diseases Society of America 1300 Wilson Boulevard, Suite 300 Arlington, VA 22209 info@idsociety.org

Home Page Education & Training Resources Practice Guidelines Journals & Publications Policy & Advocacy Meetings About IDSA